<DOC>
	<DOCNO>NCT02431624</DOCNO>
	<brief_summary>The purpose study assess adhesion BTDS patch 40 µg/h .</brief_summary>
	<brief_title>An Assessment Buprenorphine Transdermal Delivery System ( BTDS ) Patch Adhesion</brief_title>
	<detailed_description>The objective show non-inferiority adhesion BTDS patch 40 µg/h compare BTDS patch 20 µg/h . Safety tolerability patch also assess .</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Provide write informed consent . 2 . Healthy male female subject age 18 55 inclusive . 3 . Female subject child bear potential must willing use two highly effective method contraception throughout study , one must include barrier method . 4 . Female subject postmenopausal ( define spontaneous amenorrhoea least 1 year ) permanently sterilise ( e.g . tubal occlusion , hysterectomy , bilateral salpingectomy ) . These subject require use contraception . 5 . Male subject willing use contraception partner throughout study 30 day completion study agree inform Investigator partner become pregnant time . 6 . Body weight range 55 100 kg BMI ≥ 18.5 ≤ 30.0 . 7 . Healthy free significant abnormal finding determine medical history , physical examination , vital sign , laboratory test ECG . 8 . The subject 's primary care physician confirm within last 12 month first dose nothing subject 's medical history would preclude enrolment clinical study . Exclusion Criteria Subjects exclude study meet follow criterion : 1 . Female subject pregnant lactating . 2 . Any history drug alcohol abuse . 3 . Any history condition might interfere drug absorption , distribution , metabolism excretion . 4 . Use opioid opioid antagonistcontaining medication past 30 day . 5 . Any history frequent nausea vomit regardless aetiology . 6 . Any history seizures symptomatic head trauma . 7 . Participation clinical drug study 90 day precede initial dose study , participation clinical drug study study . 8 . Any significant illness 4 week precede entry study . 9 . A history additional risk factor Torsades de Pointes ( e.g . heart failure , hypokalaemia , personal family history long QT syndrome , syncope , family history sudden death ) . 10 . Abnormal cardiac condition include follow : QTcF interval great 450 msec screen checkin first dose . Increase QTcF 60 msec predose value study period QTcF &gt; 500 msec time study . 11 . Use medication within 5 time halflife minimum 14 day prescription medication 7 day overthecounter preparation ( include vitamin , herbal and/or mineral supplement ) , whichever longer , first dose study treatment study ( exception continue use Hormone Replacement Therapy ( HRT ) contraceptives ) . 12 . Refusal abstain caffeine xanthine contain beverage grapefruit juice within 48 hour IMP administration last study measure perform study period . 13 . Weekly alcohol intake exceed equivalent 14 units/week female 21 units/week male . 14 . Consumption alcoholic beverage within 48 hour IMP administration , refusal abstain alcohol duration study confinement least 48 hour last naltrexone dose study period . 15 . History smoking within 45 day IMP administration refusal abstain smoking study . 16 . Positive result urine drug screen , alcohol test pregnancy test . 17 . Known sensitivity buprenorphine , naltrexone , related compound excipients contraindication detail Butrans Summary Product Characteristics Nemexin Summary Product Characteristics . 18 . Clinically significant history allergic reaction wound dressing elastoplast . 19 . Subjects dermatological disorder tattoo propose site patch application , history eczema/cutaneous atrophy . 20 . Subjects allow hair remove propose patch application site may prevent proper placement patch . 21 . Refusal allow primary care physician inform participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Healthy Volunteer</keyword>
</DOC>